Exercise and the Menstrual Cycle in Type 1 Diabetes
Recruiting now NCT05188014
Run by University of Alberta · for 18 to 50 · Women
What this study is about
Female participants with type 1 diabetes using oral contraceptives will be asked to wear a continuous glucose monitor for at least three days on two separate occasions (once during the last week of active pills and once during the no pill/placebo pill phase of the menstrual cycle). An exercise session (45 minutes of aerobic exercise at 60% VO2peak on a cycle ergometer) will take place at 5 pm on the second day of glucose monitoring.
Who can join (things the study team will check)
✅ You may be able to join if…
- type 1 diabetes diagnosed for at least 1 year
- regular menses
- using monophasic oral contraceptives
- residing in Edmonton, Alberta and able to visit the lab at the University of Alberta
🚫 You may not be able to join if…
- HbA1c > 9.9%
- frequent and unpredictable hypoglycemia
- change in insulin management strategy within two months of the study
- use of an automated insulin delivery system
- blood pressure > 140/95
- history of cardiovascular disease
- severe peripheral neuropathy
- active proliferative retinopathy
- use of medications (other than insulin) that would affect blood glucose levels
- any musculoskeletal condition that would contraindicate exercise (e.g. sprain, strain, joint injury, etc.)
Where this trial is running
- Alberta Diabetes Institute, Edmonton, Alberta, Canada
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.